Last reviewed · How we verify
Becaplermin users
Stimulates wound healing by promoting the proliferation and differentiation of keratinocytes and fibroblasts
Stimulates wound healing by promoting the proliferation and differentiation of keratinocytes and fibroblasts Used for Ulcerative wounds.
At a glance
| Generic name | Becaplermin users |
|---|---|
| Sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Drug class | PDGF analog |
| Target | PDGF |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
Becaplermin is a recombinant human platelet-derived growth factor (PDGF) that stimulates wound healing by promoting the proliferation and differentiation of keratinocytes and fibroblasts.
Approved indications
- Ulcerative wounds
Common side effects
- Application site reaction
- Skin irritation
- Pruritus
Key clinical trials
- The Risk of Cancer in Users of Regranex (Becaplermin) and Matched Comparators (Nonusers of Regranex [Becaplermin])
- Becaplermin Use and Cancer Risk in a Patient Population of U.S. Veterans With Diabetes
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Becaplermin users CI brief — competitive landscape report
- Becaplermin users updates RSS · CI watch RSS
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. portfolio CI